Optimisation of patient-reported outcome measurement for haematological cancer patients receiving novel immunotherapies: perspectives of multi-stakeholders - Top-Institutions - MDSpire

Optimisation of patient-reported outcome measurement for haematological cancer patients receiving novel immunotherapies: perspectives of multi-stakeholders

By
Eilidh M Duncan
Jhulia Salviano
Charalampia Kyriakou
Samantha Nier
Simone Oerlemans
Sam Salek
Kate Morgan
Katie Joyner
May 4, 2026
0 min

Frontiers In Hematology

Share

Top Institutions in Oncology

Brief introduction explaining scope and methodology.

#1

Memorial Sloan Kettering Cancer Center

New York, New York
Key Differentiators
- Hematology
- Oncology
#2

University of Texas MD Anderson Cancer Center

Houston, Texas
Key Differentiators
- Hematology
- Oncology
#3

Massachusetts General Hospital

Boston, Massachusetts
Key Differentiators
- Hematology
- Oncology
#4

University of North Carolina

Chapel Hill, North Carolina
Key Differentiators
- Hematology
- Oncology
#5

Erasmus MC

Rotterdam, Netherlands
Key Differentiators
- Hematology
- Oncology

Original Source(s)

Frontiers In Hematology

Optimisation of patient-reported outcome measurement for haematological cancer patients receiving novel immunotherapies: perspectives of multi-stakeholders

by Eilidh M Duncan, Jhulia Salviano, Charalampia Kyriakou, Samantha Nier, Simone Oerlemans, Sam Salek, Kate Morgan, Katie Joyner
May 4, 2026

Related Content

Blood Cancer Journal (Nature Portfolio)

Enterocolitis Associated with Immune Effector Cells Following BCMA-Targeted CAR T-Cell Therapy: Findings from a Multicenter Case Series

Frontiers In Oncology

Prognostic nutritional index, but not NLR or PLR, is linked to survival in multiple myeloma

by Nermin Keni Begendi, Mustafa Duran, Yaşar Culha
May 28, 2026

Frontiers In Hematology

Mechanisms of kinase inhibitor resistance in subtypes of cutaneous T-cell lymphomas